Vandana Seeram, MD
Critical Care Medicine · Jacksonville, FLNPI 1215081252
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,061 of the $4,352 with a category attached, or 70.3%. Intuitive Surgical accounts for 74.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $3,259 and has fallen 98.1% since, to $62 in 2025.
Across 29 payments — averaging $150.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Merit Medical Systems Inc$779
- Johnson & Johnson$180
- United Therapeutics Corporation$61
- Ambu Inc.$27
- GSK$20
- plus $26 from 2 others
Across 106 payments — averaging $2775.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$234K
- GSK$23K
- Janssen Research & Development, LLC$21K
- Actelion Pharmaceuticals US, Inc.$9K
- AstraZeneca$6K
What the payments were for
- Travel & lodging$50912%
- Food & beverage$78218%
- Education$3,06170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $3,259 |
| Merit Medical Systems Inc | 8 | $779 |
| Johnson & Johnson | 2 | $180 |
| United Therapeutics Corporation | 6 | $61 |
| Ambu Inc. | 1 | $27 |
| GSK | 1 | $20 |
| Amgen | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,118
- AERO Stent & del system$350
- AEROMini Fully Covered Tracheobronchial Stent$339
- MONARCH$141
How this compares
$4,352 in reported general payments places this provider in the 85th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 99 | $1,355,551 |
| UptraviSelexipag | 55 | $1,230,181 |
| OpsumitMacitentan | 83 | $1,057,424 |
| Tyvaso DpiTreprostinil | 38 | $855,834 |
| LetairisAmbrisentan | 61 | $773,521 |
| Ambrisentan | 159 | $661,719 |
| Orenitram ErTreprostinil Diolamine | 36 | $624,129 |
| WinrevairSotatercept-Csrk | 29 | $433,691 |
| OfevNintedanib Esylate | 25 | $329,818 |
| TezspireTezepelumab-Ekko | 38 | $157,459 |
| XolairOmalizumab | 36 | $132,764 |
| Fasenra PenBenralizumab | 18 | $108,152 |
| Tadalafil | 133 | $78,776 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $64,955 |
| NucalaMepolizumab | 13 | $55,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $11 | $2,287,605138 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $20 | $146,686148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in Jacksonville
- Eddy GutierrezJacksonville$315K
- Nathan WaldronJacksonville$17K
- Pramod GuruJacksonville$11K
- Joseph ShiberJacksonville$10K
- Jorge TrabancoJacksonville$7K
- Louis GuzziOrlando$635K
- Fortune AlabiKissimmee$587K
- Debabrata BandyopadhyayTampa$398K
- Fred UmehKissimmee$371K
- Amit TandonWesley Chapel$338K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.